Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Mar 31:10:21.
doi: 10.21037/tgh-24-139. eCollection 2025.

LOAd703 and chemotherapy combination in pancreatic cancer: insights from the LOKON001 study

Ziad Abuhelwa  1   2 , Dae Won Kim  1
Affiliations
Editorial

LOAd703 and chemotherapy combination in pancreatic cancer: insights from the LOKON001 study

Ziad Abuhelwa et al. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: Pancreatic cancer; clinical trial; oncolytic virus.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-139/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12-49. 10.3322/caac.21820 - DOI - PubMed
    1. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013;31:23-9. 10.1200/JCO.2012.44.4869 - DOI - PubMed
    1. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023;402:1272-81. 10.1016/S0140-6736(23)01366-1 - DOI - PMC - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. 10.1056/NEJMoa1304369 - DOI - PMC - PubMed
    1. Basso D, Fogar P, Falconi M, et al. Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. PLoS One 2013;8:e54824. 10.1371/journal.pone.0054824 - DOI - PMC - PubMed

LinkOut - more resources